End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) overview

End-stage kidney disease, also called end-stage renal disease (ESRD), refers to complete or almost complete kidney failure. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion, and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis, and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

For a complete picture of PTSR and LoA scores for drugs in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.